Ir para o conteúdo principal

MIRA Pharmaceuticals (NASDAQ: MIRA) — Perfil da empresa, notícias e dados financeiros

Logo de MIRA Pharmaceuticals
MIRA MIRA Pharmaceuticals
MIRA Pharmaceuticals  primary media
Perfil da empresa

MIRA Pharmaceuticals

MIRA Pharmaceuticals (NASDAQ:MIRA) is a dynamic player in the biotechnology sector, focused on developing innovative treatments to address unmet medical needs. The company's operations span from early-stage research to clinical trials, with projects targeting a variety of diseases. MIRA Pharmaceuticals aims to revolutionize patient care through groundbreaking therapies, leveraging the latest scientific discoveries and a highly skilled team. Their portfolio includes potential treatments for rare diseases, chronic conditions, and life-threatening illnesses, underscoring their commitment to improving health outcomes worldwide. With a forward-thinking approach, MIRA Pharmaceuticals strives to lead the way in biopharmaceutical advancements, ensuring better and more accessible treatments for patients around the globe.

Resumo

Public USParticipação acionária
2020Ano de fundação
3Funcionários
Miami, United StatesSede
Carregando mapa...
Presença global

Operações

Todos os locais
Miami, US

Produtos e/ou serviços de MIRA Pharmaceuticals

  • Development of innovative oncology drugs targeting resistant cancer cells.
  • Research on personalized medicine approaches for effective cancer treatments.
  • Advanced diagnostic tools for early detection of various cancers.
  • Collaboration on biotechnological advancements in gene therapy.
  • Manufacturing high-quality, affordable generic medications for widespread health issues.
  • Provision of specialized consulting services to healthcare providers on drug management and patient care.

equipe executiva do MIRA Pharmaceuticals

  • Erez AminovCEO & Chairman
  • Andriy MushakChief Financial Officer
  • Itzchak AngelChief Scientific Advisor

Principais indicadores financeiros

Resultados divulgados pela MIRA Pharmaceuticals , em USD.

Cap. de mercado
23,4 mi
Receita (TTM)
0
P/L
—
LPA (diluído, TTM)
-1.2
Dividend yield
—
Margem de lucro
0.0%
Receita e lucro anuais da MIRA Pharmaceuticals
Fim do ano fiscalReceitaResultado operacionalLucro líquido
0-10,5 mi-10,4 mi
0-8 mi-7,9 mi
0-8,5 mi-12 mi
0-7 mi-7,1 mi